Showing papers by "Pierre Larochelle published in 2012"
McGill University1, University of British Columbia2, University of Calgary3, University of Ottawa4, Memorial University of Newfoundland5, University of Western Ontario6, University of Toronto7, University of Alberta8, Ottawa Hospital Research Institute9, Université du Québec à Trois-Rivières10, Montreal General Hospital11, Jewish General Hospital12, University of Saskatchewan13, Canadian Stroke Network14, Hôpital Maisonneuve-Rosemont15, Laval University16, University Health Network17, Queen Elizabeth II Health Sciences Centre18, Université de Sherbrooke19, St. Michael's Hospital20, University of Manitoba21, Université de Montréal22, Concordia University23, Lawson Health Research Institute24, Department of National Defence25
TL;DR: Use of home blood pressure monitoring to confirm a diagnosis of white coat syndrome and the recent evidence on blood pressure targets for patients with hypertension and diabetes are reviewed and continue to recommend a blood pressure target of less than 130/80 mm Hg.
241 citations
TL;DR: The guiding principles suggested here summarize the consensus of opinions on the diagnosis and management of vegf-i-induced hypertension during treatment of mrcc obtained from an expert working group composed of 4 medical oncologists and 5 Canadian hypertension specialists.
Abstract: Inhibitors of the vascular endothelial growth factor (vegf-is) signalling pathway have fundamentally changed the treatment of metastatic renal cell carcinoma (mrcc). Hypertension is one of the most common side effects of vegf-is and has been reported with almost every vegf-i used for treatment to date. The exact mechanism of vegf-i–induced hypertension appears complex and multifactorial, and it remains to be fully explained. No randomized clinical trials are available to guide the management of hypertension during vegf-i treatment in mrcc patients. The guiding principles suggested here summarize the consensus of opinions on the diagnosis and management of vegf-i–induced hypertension during treatment of mrcc obtained from an expert working group composed of 4 Canadian medical oncologists and 5 Canadian hypertension specialists. The Canadian Hypertension Education Program guidelines, available literature, and expert opinion were used to develop the guiding principles.
26 citations